Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose monthly emicizumab prophylaxis in Thai hemophilia A patients with and without inhibitor
TCTR20210725001Enrolling by invitation
- Sponsor
- Division of Pediatric Hematology
- Start
- Mar 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Division of Pediatric Hematology. Started Mar 2021; status: enrolling by invitation.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on TCTR20210725001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210725001.